Overall, these findings strongly prove the direct link between FGF/FGFR and c-Myc, identify the FGF/FGFR/c-Myc axis as a new therapeutic target for the treatment of MM and indicate that FGF/FGFR inhibitors can represent an efficient strategy to target the FGF/FGFR/c-Myc axis in MM cells (Fig. 7). The gene discussed is MYC; the disease is Miyoshi myopathy.